Switch theme
Sign up to access all valuation multiples
Biosynex SA is engaged in the research, development, and manufacturing of fast diagnosis tests on membrane support for health professionals. It manufactures and markets medical devices for screening, diagnosis.
2005
128
LTM Revenue n/a
LTM EBITDA n/a
$70.5M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Biosynex has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Biosynex achieved revenue of $96.9M and an EBITDA of -$6.5M.
Biosynex expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Biosynex valuation multiples based on analyst estimates| FY 2022 | FY 2023 | FY 2024 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $205M | $96.9M | n/a | n/a | XXX |
| Gross Profit | $215M | $107M | $51.2M | XXX | XXX |
| Gross Margin | 105% | 110% | NaN% | XXX | XXX |
| EBITDA | $59.6M | -$6.5M | n/a | n/a | XXX |
| EBITDA Margin | 29% | -7% | NaN% | NaN% | XXX |
| Net Profit | $108M | $16.3M | -$38.5M | XXX | XXX |
| Net Margin | 53% | 17% | NaN% | XXX | XXX |
| Net Debt | n/a | n/a | $45.6M | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of February 21, 2025, Biosynex's stock price is EUR 1 (or $1).
Biosynex has current market cap of EUR 15.5M (or $16.2M), and EV of EUR 67.6M (or $70.5M).
See Biosynex trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $70.5M | $16.2M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of February 21, 2025, Biosynex has market cap of $16.2M and EV of $70.5M.
Biosynex's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Biosynex's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Biosynex and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $70.5M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpBiosynex's NTM/LTM revenue growth is n/a
Biosynex's revenue per employee for the last fiscal year averaged $0.8M, while opex per employee averaged $0.7M for the same period.
Over next 12 months, Biosynex's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Biosynex's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Biosynex and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.8M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.7M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | 88% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Electromed | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Biosynex acquired XXX companies to date.
Last acquisition by Biosynex was XXXXXXXX, XXXXX XXXXX XXXXXX . Biosynex acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Biosynex founded? | Biosynex was founded in 2005. |
| Where is Biosynex headquartered? | Biosynex is headquartered in France. |
| How many employees does Biosynex have? | As of today, Biosynex has 128 employees. |
| Who is the CEO of Biosynex? | Biosynex's CEO is Mr. Larry Abensur. |
| Is Biosynex publicy listed? | Yes, Biosynex is a public company listed on PAR. |
| What is the stock symbol of Biosynex? | Biosynex trades under ALBIO ticker. |
| When did Biosynex go public? | Biosynex went public in 2011. |
| Who are competitors of Biosynex? | Similar companies to Biosynex include e.g. Philips, Perspective Therapeutics, Electromed, InfuSystem. |
| What is the current market cap of Biosynex? | Biosynex's current market cap is $16.2M |
| Is Biosynex profitable? | Yes, Biosynex is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
